In Brief: Venisect
This article was originally published in The Gray Sheet
Venisect: Firm's Laser Lancet 510(k) requires additional information, FDA tells firm. LaBarge, Inc., which holds exclusive manufacturing rights to the laser device used for taking blood samples, says "Venisect intends to respond expeditiously," although clearance "could possibly be delayed several months." The request for additional information is the third FDA has made since submission of the 510(k) in December 1995 ("The Gray Sheet" Feb. 5, I&W-6)...
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.